Willems, Laurent M.
Rosenow, Felix
Schubert-Bast, Susanne
Kurlemann, Gerhard
Zöllner, Johann Philipp
Bast, Thomas
Bertsche, Astrid
Bettendorf, Ulrich
Ebrahimi-Fakhari, Daniel
Grau, Janina
Hahn, Andreas
Hartmann, Hans
Hertzberg, Christoph
Hornemann, Frauke
Immisch, Ilka
Jacobs, Julia
Klein, Karl Martin
Klotz, Kerstin A.
Kluger, Gerhard
Knake, Susanne
Knuf, Markus
Marquard, Klaus
Mayer, Thomas
Meyer, Sascha
Muhle, Hiltrud
Müller-Schlüter, Karen
von Podewils, Felix
Ruf, Susanne
Sauter, Matthias
Schäfer, Hannah
Schlump, Jan-Ulrich
Syrbe, Steffen
Thiels, Charlotte
Trollmann, Regina
Wiemer-Kruel, Adelheid
Wilken, Bernd
Zukunft, Bianca
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Accepted: 21 June 2021
First Online: 17 July 2021
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. This work was supported by the federal state Hessen with a LOEWE grant to the Center of Personal and Translational Epilepsy Research (CePTER).
: Laurent M. Willems has no conflicts of interest that are directly relevant to the content of this article. Felix Rosenow reports personal fees from Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals, Novartis, Medtronic, and UCB and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse and the European Union. Susanne Schubert-Bast reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, LivaNova, UCB and Zogenix. Gerhard Kurlemann reports personal fees from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, UCB, Novartis, Takeda and Zogenix. Johann Philipp Zöllner reports speakers’ honoraria and travel grants from Eisai and Desitin Arzneimittel. Thomas Bast reports personal fees from Eisai, Desitin Arzneimittel, GW Pharma, Novartis, Nutricia, Shire, Takeda, UCB Pharma and Zogenix. Astrid Bertsche reports personal fees from Desitin Arzneimittel GmbH, Eisai GmbH, GW Pharma GmbH, Shire/Takeda GmbH, UCB Pharma GmbH and ViroPharma GmbH. Daniel Ebrahimi-Fakhari reports personal fees from GW Pharmaceuticals companies. Christoph Hertzberg reports personal fees from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Novartis, Shire and Zogenix. Ilka Immisch reports personal fees from UCB Pharma GmbH. Julia Jacobs reports personal fees from Eisai, GW Pharmaceuticals companies and Zogenix and has been supported by the German Research Foundation (DFG; JA 1725/4-1). Karl Martin Klein reports personal fees from UCB Pharma, Novartis Pharma AG, Eisai and GW Pharmaceuticals, grants from the federal state Hessen through the LOEWE program and grants from the Canadian Institutes of Health Research. Kerstin A. Klotz reports personal fees from GW Pharmaceuticals companies and Zogenix and was supported by the Berta-Ottenstein-Program for Clinician Scientists from the Faculty of Medicine, University of Freiburg. Gerhard Kluger reports personal fees from Desitin Arzneimittel, Eisai and Zogenix. Susanne Knake reports speaker’s honoraria from Arvelle, Eisai, Epilog and UCB. Thomas Mayer reports personal fees and grants from Arvelle Therapeutics, Eisai, GW Pharmaceuticals companies, UCB and Zogenix. Sascha Meyer reports grants from Novartis, UCB, Shire, Deutsche Forschungsgemeinschaft and Epilepsiestiftung Dr. Wolf. Hiltrud Muhle reports personal fees from Desitin Arzneimittel, UCB, Novartis and Zogenix. Karen Müller-Schlüter reports personal fees from Nutricia, Desitin Arzneimittel, Shire, Medice, Novartis and UCB. Felix von Podewils reports personal fees and grants from Bial, Desitin Arzneimittel, Eisai, GW Pharmaceutical companies, Arvelle Therapeutics, Zogenix and UCB Pharma. Matthias Sauter reports personal fees from Novartis and GW Pharmaceuticals companies. Regina Trollmann reports personal fees from Eisai, Desitin, PTC Therapetics, Roche and Sanofi Genzyme. Adelheid Wiemer-Kruel reports personal fees from Desitin Arzneimittel, GW Pharmaceuticals companies, Nutricia GmbH, Vitaflo and UCB. Bernd Wilken reports fees and compensation for travel expenses from Eisai, Takeda/Shire, Ipsen and PharmAllergan. Adam Strzelczyk reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, LivaNova, Marinus Pharma, Medtronic, UCB and Zogenix. Ulrich Bettendorf, Janina Grau, Andreas Hahn, Hans Hartmann, Frauke Hornemann, Markus Knuf, Klaus Marquard, Susanne Ruf, Hannah Schäfer, Jan-Ulrich Schlump, Steffen Syrbe, Charlotte Thiels and Bianca Zukunft have no competing interests.
: This study received the approval of the local Ethics Committee of Goethe-University, Frankfurt am Main, Germany.
: Informed consent by the patient or legal guardian was mandatory to participate in this study.
: All participants in the study or their legal guardians consented to the publication of the collected data in an anonymised form when they were included in the study.
: Anonymised data will be made available on reasonable request, with respect to the German General Data Protection Regulation (Datenschutz-Grundverordnung, DGSVO).
: Not applicable.
: LMW, FR, SSB, GKu and AS developed the idea for this analysis. LMW and AS conceived the paper, performed the statistical analysis and wrote the first draft. LMW, FR, SSB, GKu, JPZ, TB, AB, UB, DEF, JG, AH, HH, CH, FH, II, JJ, KMK, KAK, GKl, SK, MK, KM, TM, SM, HM, KMS, FvP, SR, MS, HS, JUS, SSy, CT, RT, AWK, BW, BZ and AS acquired patient data, edited the manuscript and discussed the results. LMW created the charts and figures. All authors contributed to the final manuscript, approved the final manuscript for publication and agree to be accountable for the work presented in the manuscript.